文献速递甲状腺疾病

妊娠期TRAb分孕期阈值预测胎儿/新生儿甲状腺功能异常

Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

这项前瞻性多中心队列研究(2010-2023,荷兰44家中心)纳入有Graves病病史(n=500)或活动性Graves病(n=178)的孕妇,用TRAK human assay检测TRAb。结果显示分孕期TRAb阈值预测风险准确性高:病史组25/19/6倍ULN的阴性预测值为100%,活动组10/12/10倍ULN的敏感性为89%/86%/83%;抗甲状腺药物治疗中母体TRAb低或下降仍可发生新生儿甲亢。

要点

  • 分孕期TRAb阈值高于临床常用的统一ULN倍数,且随孕周和疾病状态不同。
  • 病史组25/19/6倍ULN的阴性预测值为100%,活动组10/12/10倍ULN敏感性89%/86%/83%。
  • 单一ULN阈值跨检测平台可能高估胎儿/新生儿Graves病,TRAb阈值需平台特异性验证。

核心结论

  • 分孕期TRAb阈值预测胎儿/新生儿甲状腺功能异常准确性高,且高于常用统一ULN倍数。
  • TRAb阈值具有检测平台特异性,单一ULN阈值可能导致误分类和过度胎儿监测。

研究设计与样本

  • 前瞻性、多中心、观察性队列研究(2010-2023),荷兰44家三级和二级中心。
  • 纳入有Graves病病史(n=500)或活动性Graves病(n=178)的孕妇。
  • 采用BRAHMS Kryptor Compact Plus分析仪上的TRAK human assay检测母体TRAb滴度。
  • 主要结局为生化确诊的胎儿/新生儿甲亢或甲减。

主要发现

  • 病史组分孕期TRAb阈值25、19、6倍ULN的阴性预测值为100%。
  • 活动组分孕期TRAb阈值10、12、10倍ULN的敏感性分别为89%、86%、83%。
  • 接受抗甲状腺药物治疗且母体TRAb低或下降的母亲仍可发生新生儿甲亢。

关键数值与推荐

  • 有Graves病病史者:分孕期TRAb阈值25、19、6倍ULN,阴性预测值100%。
  • 活动性Graves病者:分孕期TRAb阈值10、12、10倍ULN,敏感性89%、86%、83%。

临床怎么用

  • 临床应使用分孕期和疾病状态特异的TRAb阈值进行风险分层,而非统一ULN倍数。
  • TRAb阈值需按检测平台进行临床验证,避免跨平台套用导致误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Transplacental transfer of thyrotropin receptor antibodies (TRAbs) during pregnancy may cause fetal/neonatal thyroid dysfunction. Current guidelines recommend a universal TRAb titer threshold, irrespective of gestational age or assay platform. However, evidence supporting trimester-specific and assay-specific thresholds is lacking. OBJECTIVE: This work aimed to determine whether trimester-specific TRAb levels predict fetal/neonatal thyroid dysfunction and to establish assay-specific cutoff values for clinical risk stratification. METHODS: In this prospective, multicenter, observational cohort study (2010-2023), maternal TRAb titers were measured using the TRAK human assay on the BRAHMS Kryptor Compact Plus analyzer. Settings were tertiary and secondary care centers (n = 44) across the Netherlands. Patients included women with a history of (n = 500) or active (n = 178) Graves disease. Main outcome measures included biochemically confirmed fetal/neonatal hyperthyroidism or hypothyroidism. RESULTS: Trimester-specific TRAb titer thresholds predicted risk with high accuracy. In women with a history of Graves disease (n = 500), trimester-specific cutoffs of 25-, 19-, and 6-fold the upper limit of normal (ULN) showed a negative predictive value of 100%. In women with active Graves (n = 178), cutoffs of 10-, 12-, and 10-fold the ULN showed sensitivities of 89%, 86%, and 83%. Neonatal hyperthyroidism occurred despite low or declining maternal TRAb levels in mothers treated with antithyroid drugs. CONCLUSION: Trimester-specific TRAb thresholds were higher than the universal ULN multipliers commonly applied in clinical practice, and differed by gestational age and disease status. Application of a single ULN-based threshold titer across different TRAb assays may result in misclassification (ie, overestimation of fetal and neonatal Graves disease) and consequently in unnecessary and resource-intensive fetal surveillance. This indicates that TRAb thresholds are assay specific and require platform-specific clinical validation, even when assays are calibrated against a common international standard.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Saleh L, Schreurs MWJ, Boersma E, et al. Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease. J Clin Endocrinol Metab. 2026. PMID: 41846542. doi:10.1210/clinem/dgag118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。